Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1

Conditions

Prostatic Neoplasms 147Breast Neoplasms 108Lung Neoplasms 93Carcinoma, Non-Small-Cell Lung 78Neoplasm Metastasis 68Glioblastoma 68Brain Neoplasms 65Glioma 59Pancreatic Neoplasms 46Carcinoma, Renal Cell 43Multiple Myeloma 41Squamous Cell Carcinoma of Head and Neck 39Colorectal Neoplasms 39Lymphoma, Large B-Cell, Diffuse 37Neoplasms 34Melanoma 33Lymphoma 32Carcinoma, Hepatocellular 32Urinary Bladder Neoplasms 31Ovarian Neoplasms 29Astrocytoma 28Sarcoma 25Oropharyngeal Neoplasms 24Lymphoma, Follicular 23Central Nervous System Neoplasms 23Rectal Neoplasms 22Uterine Cervical Neoplasms 21Triple Negative Breast Neoplasms 21Mouth Neoplasms 21Lymphoma, Non-Hodgkin 21

Interventions

Taxes 2Paclitaxel 2Magnetic Resonance Spectroscopy 2olaparib 1liposomal doxorubicin 1copanlisib 1Topotecan 1Specimen Handling 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Bevacizumab 1ASTX-660 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Platinum-Refractory Fallopian Tube Carcinoma × Magnetic Resonance Spectroscopy × Clear all
NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma

NCT05295589 2023-09-26

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gynecologic

Platinum-Refractory Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡